Latest Conference Coverage


Ozanimod Lowers ARR, Reduces Grey Matter Loss Compared to Interferon Beta-1a

Ozanimod Lowers ARR, Reduces Grey Matter Loss Compared to Interferon Beta-1a

September 11th 2019

Data from the phase 3 SUNBEAM trial of the sphingosine 1-phosphate receptor modulator have suggested that the Celgene treatment lowers annualized relapse rates and reduces the rate of cortical gray matter loss, improving cognition measures, compared to IFN-ß1a.


R. Edward Hogan, MD: Diazepam Nasal Spray Offers Benefits and Long-Term Safety

R. Edward Hogan, MD: Diazepam Nasal Spray Offers Benefits and Long-Term Safety

September 10th 2019

The director of the adult epilepsy center at Washington University in St. Louis spoke about the use of diazepam nasal spray in patients with epilepsy ­and detailed the advantages it offers these patients and their physicians.


Danielle Andrade, MD, MSc: Transitioning Patients With Epilepsy to Adult Care

Danielle Andrade, MD, MSc: Transitioning Patients With Epilepsy to Adult Care

September 10th 2019

The professor of medicine, neurology, at the University of Toronto spoke to the hurdles faced by both pediatric and adult neurologists when transitioning a patient with epilepsy from childhood care to adult care.


Richard Lipton, MD: Interpreting Eptinezumab's Impact on HIT-6 Score

Richard Lipton, MD: Interpreting Eptinezumab's Impact on HIT-6 Score

September 9th 2019

The director of the Montefiore Headache Center will provide further insight into migraine care at the 1st Annual International Congress on the Future of Neurology, to be held September 27-28 in New York City.


Ofatumumab Superior to Teriflunomide in Relapsing Multiple Sclerosis

Ofatumumab Superior to Teriflunomide in Relapsing Multiple Sclerosis

September 7th 2019

Novartis’ CD20+ B cell- targeting, fully-human antibody has outperformed teriflunomide (Aubagio) in a pair of phase 3 studies. The top-line data were presented at ECTRIMS 2019 in Stockholm, Sweden.


Paul Durham, PhD: A Combination Approach With nVNS in Migraine

Paul Durham, PhD: A Combination Approach With nVNS in Migraine

September 6th 2019

The distinguished professor and director of cell biology at Missouri State University discussed the use of nVNS in migraine treatment and whether or not it can replace the use of or be used in conjunction with triptans—a medication on which many patients fail or report poor response on.


Bruce Cree, MD, PhD, MAS: Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Bruce Cree, MD, PhD, MAS: Inebilizumab in Neuromyelitis Optica Spectrum Disorder

September 5th 2019

The clinical research director of the University of California, San Fransciso’s Multiple Sclerosis Center discussed the findings of a 230-patient study of inebilizumab versus placebo in NMOSD.


Paul Durham, PhD: Noninvasive Vagus Nerve Stimulation

Paul Durham, PhD: Noninvasive Vagus Nerve Stimulation

September 4th 2019

The distinguished professor and director of cell biology at Missouri State University discussed the findings of a model of nVNS which suggested it operates through a novel mechanism compared to available migraine therapies.


The Impact of Noninvasive Epilepsy Interventions

The Impact of Noninvasive Epilepsy Interventions

August 27th 2019

The director of comprehensive epilepsy center and professor of neurology at Thomas Jefferson University spoke to the evolution of epilepsy interventions over the last decade and its effect on the level of care for patients.


Rebecca Stainman, MD: Identifying, Addressing Physician Burnout

Rebecca Stainman, MD: Identifying, Addressing Physician Burnout

August 22nd 2019

The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.


Trends in Migraine Care Reveal Treatment Gaps and Education Barriers

Trends in Migraine Care Reveal Treatment Gaps and Education Barriers

August 19th 2019

The director of the MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the ongoing efforts in drug development and what the ideal future may hold for migraine medicine.


Dementia Emergency Department Use Can Be Reduced With Specialized Telemedicine

Dementia Emergency Department Use Can Be Reduced With Specialized Telemedicine

August 17th 2019

The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health discussed the impact that telemedicine, conducted in senior living communities, can have on emergency department visits for individuals with dementia.


Annette Langer-Gould, MD, PhD: Lowering Postpartum MS Relapse Rates With Breastfeeding

Annette Langer-Gould, MD, PhD: Lowering Postpartum MS Relapse Rates With Breastfeeding

August 16th 2019

The regional lead in clinical and translational neuroscience at Kaiser Permanente discussed subgroup findings from a study of pregnancy in women with MS which suggested that breastfeeding in the postpartum period can drastically decrease the risk of disease relapse.


Antje Bischof, MD: Understanding Vasculitic Neuropathy

Antje Bischof, MD: Understanding Vasculitic Neuropathy

August 15th 2019

The postdoctoral scholar at the University of California San Francisco discussed the findings from her study that gives comprehensive insight into prevalence and organ associations of vasculitic neuropathy.


Joseph Berger, MD: The Role of Artificial Intelligence in Neurology

Joseph Berger, MD: The Role of Artificial Intelligence in Neurology

August 15th 2019

The associate chief of the MS division and professor of neurology at Penn Medicine described the ongoing relationship between artificial intelligence and neurologists, and how it may evolve in the future.


Nina Riggins, MD, PhD: Predicting Outcomes of Botox Treatment in Chronic Migraine

Nina Riggins, MD, PhD: Predicting Outcomes of Botox Treatment in Chronic Migraine

August 14th 2019

The assistant professor and neurologist at the University of California San Francisco discussed how the presence of cranial autonomic symptoms (CAS) can be a predictor of the effect of Botox on chronic migraine.


Joseph Berger, MD: Can AI Replace Neurologists?

Joseph Berger, MD: Can AI Replace Neurologists?

August 14th 2019

The associate chief of the MS division and professor of neurology at Penn Medicine spoke to neurologist’s reliance on physical examination, and how the use of almost-rudimentary but longstanding tools allow for critical 1-on-1 time with the patient.


Annette Langer-Gould, MD, PhD: No Increased Risk for Postpartum MS Relapses

Annette Langer-Gould, MD, PhD: No Increased Risk for Postpartum MS Relapses

August 13th 2019

The regional lead in clinical and translational neuroscience at Kaiser Permanente spoke about the findings of a recent study of pregnancy in women with MS which showed no increased risk of relapse during the postpartum period.


Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease

Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease

August 13th 2019

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of Alzheimer disease.


David Irwin, MD: Differentiating Dementias in Living Patients

David Irwin, MD: Differentiating Dementias in Living Patients

August 12th 2019

The assistant professor and cognitive neurologist at the University of Pennsylvania Frontotemporal Degeneration Center will share additional insights on Alzheimer disease at the upcoming International Congress on the Future of Neurology, taking place September 27-28, 2019 in New York City.


Kathryn Davis, MD, MSTR: Off-Label Clobazam Use in Refractory Epilepsy

Kathryn Davis, MD, MSTR: Off-Label Clobazam Use in Refractory Epilepsy

August 9th 2019

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania discussed the findings of a single-center review of off-label clobazam use for patients with drug-refractory epilepsy.


Kathryn Davis, MD, MSTR: Treatment Considerations for Women With Epilepsy

Kathryn Davis, MD, MSTR: Treatment Considerations for Women With Epilepsy

August 8th 2019

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania shared insight into the prioritization of women with epilepsy who may intend to get pregnant.


Jelena Pavlovic, MD, PhD: Perimenstrual-Related Migraine

Jelena Pavlovic, MD, PhD: Perimenstrual-Related Migraine

August 8th 2019

The attending neurologist at the Montefiore Headache Center and assistant professor of neurology at the Albert Einstein College of Medicine spoke about preventive treament for perimenstrual-related migraine.


Sarah Wilson, PhD: Long-Term Social Outcomes of Epilepsy Surgery

Sarah Wilson, PhD: Long-Term Social Outcomes of Epilepsy Surgery

August 7th 2019

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the results of a study she and colleagues conducted in which they mapped the long-term social outcomes of patient post-epilepsy surgery.


Alon Ironi: Nerivio Migra Reduces Excess Medication Use in Migraine

Alon Ironi: Nerivio Migra Reduces Excess Medication Use in Migraine

August 6th 2019

The CEO and co-founder of Theranica discussed the migraine treatment device’s mechanism of action and its successes in reducing medication overuse headache.


Sarah Wilson, PhD: Managing Post-Operative Patients With Epilepsy

Sarah Wilson, PhD: Managing Post-Operative Patients With Epilepsy

August 5th 2019

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne detailed how the transition from states of illness to wellness after epilepsy surgery can result not just in brain changes, but psychosocial challenges for patients.


Episode 1: State of CBD: Not All Cannabidiol Is Created Equal

Episode 1: State of CBD: Not All Cannabidiol Is Created Equal

August 5th 2019

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.


Can Telemedicine Make a Difference in Neurology Subspecialties?

Can Telemedicine Make a Difference in Neurology Subspecialties?

August 5th 2019

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.


What Role Do Genetics Play in Determining Alzheimer Disease Risk?

What Role Do Genetics Play in Determining Alzheimer Disease Risk?

August 2nd 2019

The professor of neurology and founding chair of the John T. Macdonald Foundation Department of Human Genetics at the University of Miami discussed the distinctions between Alzheimer disease risk of ethnicities that share genetic markers.


Noah Rosen, MD: Evaluation of Cardiovascular Risks of Galcanezumab in Episodic, Chronic Migraine

Noah Rosen, MD: Evaluation of Cardiovascular Risks of Galcanezumab in Episodic, Chronic Migraine

August 2nd 2019

The program director of neurology at the Zucker School of Medicine, Northwell Health, spoke about the great advances of the new CGRP medications available for the prevention of migraine.

© 2024 MJH Life Sciences

All rights reserved.